Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients

[1]  M. Pierotti,et al.  p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Piccart,et al.  The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  R. Vossen,et al.  Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. , 2000, Cancer research.

[4]  B. Iacopetta,et al.  Routine analysis of p53 mutation in clinical breast tumor specimens using fluorescence-based polymerase chain reaction and single strand conformation polymorphism. , 2000, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[5]  B. Iacopetta,et al.  Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  J. Cunningham,et al.  A prospective trial of midwest breast cancer patients: A p53 gene mutation is the most important predictor of adverse outcome , 2000, International journal of cancer.

[7]  P. Chappuis,et al.  Prognostic significance of p53 mutation in breast cancer: Frequent detection of non‐missense mutations by yeast functional assay , 1999, International journal of cancer.

[8]  C Caldas,et al.  Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis , 1999, British Journal of Cancer.

[9]  G. Hortobagyi,et al.  Recent developments in breast cancer therapy. , 1999, Seminars in oncology.

[10]  M. Gnant,et al.  Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group. , 1999, European journal of cancer.

[11]  F. Monti,et al.  Prognosis and prediction of response in breast cancer: the current role of the main biological markers , 1998, Cell proliferation.

[12]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[13]  M. Clarke,et al.  Meta-analyses, multivariate analyses, and coping with the play of chance , 1998, The Lancet.

[14]  B. Iacopetta,et al.  Detection of p53 gene mutation by rapid PCR‐SSCP and its association with poor survival in breast cancer , 1997, International journal of cancer.

[15]  C. de Toma,et al.  Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  B. Iacopetta,et al.  A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[17]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[18]  D. Horsfall,et al.  Relationship between p53 gene abnormalities and other tumour characteristics in breast‐cancer prognosis , 1996, International journal of cancer.

[19]  L. Holmberg,et al.  p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L. Holmberg,et al.  Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.

[21]  M. Espié,et al.  p53 mutations and overexpression in locally advanced breast cancers. , 1994, British Journal of Cancer.

[22]  M. Gnant,et al.  TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.